Sarepta Therapeutics (SRPT) Set to Announce Quarterly Earnings on Thursday

Key Points

• Sarepta Therapeutics is expected to report Q3 2026 results after Thursday’s market close, November 5. Analysts forecast earnings of $0.074 per share and revenue of $352.20 million.
• In the previous quarter, Sarepta reported EPS of $0.64, beating estimates of $0.22, while revenue reached $401.25 million. However, revenue declined 34.3% year over year and the company posted a negative net margin.
• Analyst sentiment is mixed but leans cautious: the stock has an average “Hold” rating and a $22.88 consensus price target, with recent firms including Zacks, Benchmark, and HC Wainwright issuing or reiterating sell ratings.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) is expected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Sarepta Therapeutics to announce earnings of $0.0740 per share and revenue of $352.20 million for the quarter. Parties may visit the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The business had revenue of $401.25 million for the quarter, compared to analysts' expectations of $366.39 million. During the same quarter in the previous year, the firm posted $2.02 earnings per share. The firm's revenue for the quarter was down 34.3% on a year-over-year basis. On average, analysts expect Sarepta Therapeutics to post $3.27 EPS for the current fiscal year and $1.34 EPS for the next fiscal year.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $19.32 on Thursday. The firm has a market capitalization of $2.04 billion, a PE ratio of -6.66, a price-to-earnings-growth ratio of 0.32 and a beta of 0.38. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics has a 12-month low of $14.68 and a 12-month high of $24.68. The firm has a 50-day moving average price of $19.26 and a 200 day moving average price of $18.76.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SRPT. Zacks Research lowered Sarepta Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday, October 5th. JPMorgan Chase & Co. cut their target price on Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating for the company in a research report on Wednesday, September 30th. Benchmark restated a "sell" rating on shares of Sarepta Therapeutics in a research report on Wednesday, September 9th. Weiss Ratings raised Sarepta Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, October 13th. Finally, HC Wainwright reiterated a "sell" rating and issued a $5.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 5th. Seven analysts have rated the stock with a Buy rating, six have assigned a Hold rating and seven have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $22.88.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc NASDAQ: SRPT is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs use RNA-based technologies, gene therapy and other genetic approaches to address the underlying causes of serious neuromuscular disorders.

The company's primary focus is Duchenne muscular dystrophy (DMD), a progressive genetic disease that causes muscle weakness and loss of function. Sarepta markets Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen), RNA-based therapies designed to help certain patients produce a shortened but functional form of dystrophin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.